Detection Rate of Liver Metastases With Contrast Enhanced Intraoperative Ultrasound Compared to Regular Imaging
Launched by ASKLEPIOS KLINIKEN HAMBURG GMBH · Jan 27, 2012
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
1. Introduction: The surgical resection of colorectal liver metastases is the only curative therapy for those patients (1). Because a major part of those patients become diagnosed in a technical irresectable stadium, most patients primary get a chemotherapy to reach a secondary resection (2). Especially for this group of patients an effective preoperative staging is necessary to know the exact number and location of the liver metastases. Standard imaging is abdominal CT with a contrast medium, lately it is also possible to create a 3D analysis based on vasculatory territories out of the 2D ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed Consent Age \> 18 years All Patients presenting with Colorectal Liver Metastasis indicated for Liver Surgery in the study period
- Exclusion Criteria:
- • No Informed Consent Possible Pregnancy Patients with hereditary diseases of the metabolic system Liver Cirrhosis CHILD B and C Renal Insufficiency defined as Kreatinin \>2,5 mg/dl PAtients enrolled in other studies
About Asklepios Kliniken Hamburg Gmbh
Asklepios Kliniken Hamburg GmbH is a leading private hospital operator in Germany, renowned for its commitment to high-quality patient care and innovative medical practices. With a strong focus on research and development, Asklepios actively engages in clinical trials to advance medical knowledge and enhance treatment options across various specialties. The organization is dedicated to fostering collaboration between healthcare professionals and researchers, ensuring the highest ethical standards and regulatory compliance in all clinical research initiatives. Through its state-of-the-art facilities and multidisciplinary approach, Asklepios Kliniken Hamburg GmbH aims to contribute significantly to the field of medicine and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Trial Officials
Gregor A Stavrou, Dr.med
Principal Investigator
Dpt. of General and Visceral Surgery, Asklepios Hospital Barmbek, Hamburg, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials